RedHill Biopharma (RDHL) Non-Current Assets (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Non-Current Assets for 3 consecutive years, with $6.1 million as the latest value for Q4 2024.

  • Quarterly Non-Current Assets fell 11.22% to $6.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2024, down 11.22% year-over-year, with the annual reading at $6.1 million for FY2024, 11.22% down from the prior year.
  • Non-Current Assets for Q4 2024 was $6.1 million at RedHill Biopharma, down from $6.9 million in the prior quarter.
  • The five-year high for Non-Current Assets was $73.0 million in Q4 2022, with the low at $6.1 million in Q4 2024.
  • Average Non-Current Assets over 3 years is $28.7 million, with a median of $6.9 million recorded in 2023.
  • The sharpest move saw Non-Current Assets crashed 90.53% in 2023, then dropped 11.22% in 2024.
  • Over 3 years, Non-Current Assets stood at $73.0 million in 2022, then plummeted by 90.53% to $6.9 million in 2023, then fell by 11.22% to $6.1 million in 2024.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $6.1 million, $6.9 million, and $73.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.